AIMC Topic: Ado-Trastuzumab Emtansine

Clear Filters Showing 1 to 2 of 2 articles

Noncirrhotic Portal Hypertension after Trastuzumab Emtansine in HER2-positive Breast Cancer as Determined by Deep Learning-measured Spleen Volume at CT.

Radiology Aug 9, 2022
Background Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate approved for use in human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Case reports have suggested an association between T-DM1 and portal hypertension. Purpo...
Humans Retrospective Studies Tomography, X-Ray Computed Female Breast Neoplasms Middle Aged Deep Learning Antineoplastic Combined Chemotherapy Protocols Capecitabine Receptor, ErbB-2 Spleen Lapatinib Hypertension, Portal Splenomegaly Ado-Trastuzumab Emtansine
View on PubMed DOI

Effects of concurrent HER2-directed therapy on development of cerebral radionecrosis after stereotactic radiotherapy: a systematic review.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] Sep 1, 2025
PURPOSE: With increasing use of human epithelial growth factor receptor two (HER2)-targeted therapies, outcomes for numerous breast cancer patients have improved. Nevertheless, patients with HER2-positive tumours face a comparatively heightened risk ...
Humans Brain Female Breast Neoplasms Brain Neoplasms Antineoplastic Agents, Immunological Combined Modality Therapy Receptor, ErbB-2 Trastuzumab Molecular Targeted Therapy Radiosurgery Radiation Injuries Necrosis Ado-Trastuzumab Emtansine
View on PubMed DOI
Popular Topics
Recent Journals